China National Pharmaceutical Group

Worldwide Vaccines Industry to 2029 - Combination Vaccines Remain a Significant Growth Contributor to Vaccine Spaces

Retrieved on: 
Friday, January 6, 2023
SEARO, Influenza, CSL Limited, Vaccine, WPRO, AMRO, Merck, Inactivated vaccine, Projection, COVID-19, Human papillomavirus infection, Pneumococcal conjugate vaccine, Anthrax Vaccine Immunization Program, GSK, Growth, Overalls, Mortality, PCV, Streptococcus pneumoniae, Mitsubishi Tanabe Pharma, Serum Institute of India, HPV, China National Pharmaceutical Group, Emergent BioSolutions, WHO, Chickenpox, Emergent, Conjugate vaccine, Pharmaceutical industry, Sanofi, Pfizer, Waldemar Haffkine

Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth.

Key Points: 
  • Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth.
  • While vaccines market (excluding COVID-19 vaccine) is expected to demonstrate nearly 11.2% growth, the market (including COVID-19 vaccine) is likely to experience 3.9% growth through the end of forecast period.
  • Epidemic, and pandemic situations like COVID-19 outbreak act as the key growth influencers for vaccines market, says a newly released market intelligence report of The publisher.
  • On the other hand, demand for seasonal influenza vaccines is projected to remain buoyant and will see the fastest growth through 2029.

CGTN: How China strengthens vaccine cooperation to battle COVID-19

Retrieved on: 
Thursday, December 15, 2022
Pfizer, Vaccination, United Arab Emirates, Transport, Omicron, Sinopec, Sinovac Biotech, Research, CanSino Biologics, Immunization, Wellcome Trust, World Health Organization, COVID-19, Vaccine, News, WHO, Safety, COVID-19 vaccine, COVAX, Risk, Pharmaceutical industry, Animal, China National Pharmaceutical Group

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.

Key Points: 
  • In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.
  • Other COVID-19 vaccine research had been carried out concurrently, including the inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm) and the inactive one from Beijing-based pharmaceutical company Sinovac.
  • As the virus keeps mutating, China has continued to advance its vaccine research over the past three years.
  • It was the first Chinese vaccine officially recognized by the WHO and the sixth vaccine approved for emergency use globally.

CGTN: How China strengthens vaccine cooperation to battle COVID-19

Retrieved on: 
Thursday, December 15, 2022
Pfizer, Vaccination, United Arab Emirates, Transport, Omicron, Sinopec, Sinovac Biotech, Research, CanSino Biologics, Immunization, Wellcome Trust, World Health Organization, COVID-19, Vaccine, News, WHO, Safety, COVID-19 vaccine, COVAX, Risk, Pharmaceutical industry, Animal, China National Pharmaceutical Group

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.

Key Points: 
  • In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.
  • Other COVID-19 vaccine research had been carried out concurrently, including the inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm) and the inactive one from Beijing-based pharmaceutical company Sinovac.
  • As the virus keeps mutating, China has continued to advance its vaccine research over the past three years.
  • It was the first Chinese vaccine officially recognized by the WHO and the sixth vaccine approved for emergency use globally.

CGTN:China to step up cooperation with Arab states under BRI, GDI, GSI

Retrieved on: 
Saturday, December 10, 2022
GSI, Speech, Arab world, Boao Forum for Asia, Conference, Poverty, Economic development, GDI, Communication, Qatar National Vision 2030, Arab Peace Initiative, Policy, COVID-19, Face, Counter-terrorism, Multilateralism, Aviation, UN, Terrorism, Health, Sport, BRI, Renewable energy, Xi, China National Pharmaceutical Group

In his talks with leaders of Arab states, Xi has constantly emphasized the vital importance of sovereignty and territorial integrity, economic development and international cooperation.

Key Points: 
  • In his talks with leaders of Arab states, Xi has constantly emphasized the vital importance of sovereignty and territorial integrity, economic development and international cooperation.
  • In his meetings with over ten political leaders of Arab states, including Palestine, Egypt, Sudan, Kuwait, Tunisia, Iraq, Xi said China sees Arab states as important forces in the multipolar world and attaches great importance to developing strategic partnerships with them.
  • During his meetings with Arab states' leaders, Xi pledged that China would continue to cooperate with its Arab counterparts in fields including anti-terrorism and poverty eradication.
  • China would also like to enhance medical and health cooperation, and promote the Chinese language education in Bahrain, Xi said.

CGTN:China to step up cooperation with Arab states under BRI, GDI, GSI

Retrieved on: 
Saturday, December 10, 2022
GSI, Speech, Arab world, Boao Forum for Asia, Conference, Poverty, Economic development, GDI, Communication, Qatar National Vision 2030, Arab Peace Initiative, Policy, COVID-19, Face, Counter-terrorism, Multilateralism, Aviation, UN, Terrorism, Health, Sport, BRI, Renewable energy, Xi, China National Pharmaceutical Group

In his talks with leaders of Arab states, Xi has constantly emphasized the vital importance of sovereignty and territorial integrity, economic development and international cooperation.

Key Points: 
  • In his talks with leaders of Arab states, Xi has constantly emphasized the vital importance of sovereignty and territorial integrity, economic development and international cooperation.
  • In his meetings with over ten political leaders of Arab states, including Palestine, Egypt, Sudan, Kuwait, Tunisia, Iraq, Xi said China sees Arab states as important forces in the multipolar world and attaches great importance to developing strategic partnerships with them.
  • During his meetings with Arab states' leaders, Xi pledged that China would continue to cooperate with its Arab counterparts in fields including anti-terrorism and poverty eradication.
  • China would also like to enhance medical and health cooperation, and promote the Chinese language education in Bahrain, Xi said.

CGTN: Infrastructure, vaccines and space: China-Arab sci-tech cooperation

Retrieved on: 
Saturday, December 10, 2022
United Arab Emirates, Belt and Road Initiative, BeiDou, China National Space Administration, Media Group, CMG, Belt, World cup, CGTN, Orangi Pilot Project, BDS, China Media Group, COVID-19, China Railway Construction Corporation, Clinical trial, Health, Kurdish Supreme Committee, Delivery, BRI, Lusail Iconic Stadium, Entertainment, Vaccine, Satellite navigation device, China National Pharmaceutical Group

China has vowed to accelerate the development of the China-Arab inter-governmental science and technology innovation cooperation mechanism.

Key Points: 
  • China has vowed to accelerate the development of the China-Arab inter-governmental science and technology innovation cooperation mechanism.
  • The country will implement more partner projects, and continue to improve the sci-tech capabilities of Arab states.
  • Lusail Stadium, the main venue for this year's World Cup, was constructed with China Railway Construction Corporation as the main contractor.
  • China and Saudi Arabia signed a memorandum of understanding on March 16, 2017, sharing the scientific data in space cooperation.

CGTN: Infrastructure, vaccines and space: China-Arab sci-tech cooperation

Retrieved on: 
Saturday, December 10, 2022
United Arab Emirates, Belt and Road Initiative, BeiDou, China National Space Administration, Media Group, CMG, Belt, World cup, CGTN, Orangi Pilot Project, BDS, China Media Group, COVID-19, China Railway Construction Corporation, Multimedia, Clinical trial, Health, Kurdish Supreme Committee, Delivery, BRI, Lusail Iconic Stadium, Entertainment, Vaccine, Satellite navigation device, China National Pharmaceutical Group

China has vowed to accelerate the development of the China-Arab inter-governmental science and technology innovation cooperation mechanism.

Key Points: 
  • China has vowed to accelerate the development of the China-Arab inter-governmental science and technology innovation cooperation mechanism.
  • Lusail Stadium, the main venue for this year's World Cup, was constructed with China Railway Construction Corporation as the main contractor.
  • Shaped like a date palm bowl or an enamel lantern, the stadium will host the World Cup final, scheduled for December 18.
  • China and Saudi Arabia signed a memorandum of understanding on March 16, 2017, sharing the scientific data in space cooperation.

Pediatric Vaccines Global Markets Report 2022: Impacts of COVID-19, Market Revenue Data for 2020 and 2021, Estimates for 2022, and CAGR Projections through 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
COVID-19, Consumer, Health, Pharmaceutical, Children, BCG, Investment, Incidence, Pfizer–BioNTech COVID-19 vaccine, CoronaVac, China National Pharmaceutical Group, Chickenpox, Pfizer, Vaccine, WHO, Dros, GlaxoSmithKline, Abbott Laboratories, Whooping cough, Mumps, Gavi, Merck & Co., Hepatitis, Measles, AstraZeneca, Global health, Child, Diphtheria, Mortality, Bharat Biotech, Vaccine-preventable diseases, Organization, COVID-19, Tetanus, UNICEF, Pharmaceutical industry

This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.

Key Points: 
  • This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.
  • The report also covers market projections through 2027 and estimates market shares for key players, as well as pediatric vaccines by type and by application.
  • The report also discusses the impact of the COVID-19 pandemic on this market.
  • Vaccines are one of the most significant advances in global health and are the most cost-effective strategy to reduce child mortality.

ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Health, Other Health, General manager, Science, NR, NASDAQ, Sinopharm Group, Securities Act of 1933, Natural health product, TGA, CEO, NHNE, Patent, OTC, NAD, European Commission, Tru, CERP, Year, Health Canada, Company, Marketing, Industry, NMN, Therapeutic Goods Administration, Risk, FSANZ, Growth, Annual report, Research, Security (finance), Multimedia, Brazilian Health Regulatory Agency, History, Watsons, Intention, Ageing, VBP, ANVISA, Drug Quality and Security Act, Sale, Fortune Global 500, SEC, JD, Life, Royal commission, Vitamin D, Â, An Act to exempt a particular class of securities from the Securities and Exchange Act, Food, US, Social media, ChromaDex, Food Standards Agency, COVID-19, China National Pharmaceutical Group

Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 30 owned and licensed patents.

Key Points: 
  • Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 30 owned and licensed patents.
  • We are honored to bring such an excellent healthy-aging product to China, said Pan Lei, General Manager of Sinopharm Xingsha.
  • Tru Niagen has also been approved by Health Canada as a Natural Health Product.
  • Sinopharm Xingsha is the health supplement division of Sinopharm Group, a top 100 Chinese nutrition and health consumer brand enterprise, and a key pharmaceutical enterprise in Fujian Province, China.

ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

Retrieved on: 
Monday, October 3, 2022
Men, Other Health, General Health, Other Retail, Lifestyle, Specialty, Consumer, Fitness & Nutrition, Retail, Women, Seniors, Vitamins, Supplements, Health, China National Pharmaceutical Group, ChromaDex, NAD, Blue, OTC, NASDAQ, Tru, Human, News, Fortune Global 500, Time, History, Private Securities Litigation Reform Act, Territory, JV, Research, Sinopharm Group, Securities Act of 1933, Industry, VBP, The Act, CEO, Twitter, FDA, Phytochemical, Human body, NR, Ageing, U.S. Securities and Exchange Commission, Science, Prospectus, Sale, Security (finance), Forward-looking statement, Vitamin D, BlueHat, Company, Cryptocurrency

The Company also announced that it entered into a securities purchase agreement for the sale of $3.1 million of its common stock in a private placement.

Key Points: 
  • The Company also announced that it entered into a securities purchase agreement for the sale of $3.1 million of its common stock in a private placement.
  • The private placement was led by existing strategic investors, and included an investment by ChromaDex CEO, Rob Fried.
  • The private placement is expected to close on or about October 7, 2022, subject to the satisfaction of customary closing conditions.
  • The shares of common stock being sold in the private placement will not have been registered under the Securities Act of 1933, as amended (the Act).